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ARSTRACT 
Objective: The aim of this study was to analyze association 
between HLA-DRBI alleles and pulmonary tuberculosis (PTB) 
in the Polish population. 
Methods: The HLA-DRBI typing was performed using 
sequence-specific amplification (polymerase chain reaction with 
sequence specific primer [PCR-SSP] in 31 patients and 58 
healthy volunteers. The DRBI primers were supplied by DYNAL 
in the standard kit DYNALaDR “low-resolution”SSP. 
Results: The study showed that the DRBl *I 6 alleles frequency 
was higher in patients with PTB than in the tested group of 
healthy controls (P < 0.01). When HL4-DR2 alleles were com- 
bined (i.e., the DRBI *15 with DRBl *16 alleles), their frequency 
was comparable with that in the healthy individuals. The high- 
est relative risk (RR) of tuberculosis was associated with 
DRBl *16 alleles (RR = 9.7). When HLA-DR6 alleles were com- 
bined (i.e., the DRBI *13 with DRBI *I 4 alleles), only a trend for 
higher frequency in patients with PTB was found. Frequency 
of DRBI *I 3 alleles of HLA-DR6 was significantly lower in PTB 
than in the healthy individuals (P < 0.001; RR = 0.04). 
Conc/usions: Results suggest that the presence of HLA- 
DRBI *16 alleles may increase the risk of development of PTB, 
whereas HLA-DRBl *I 3 alleles may be resistant to tuberculosis. 
Key Words: HLA-DRBl alleles, Polish population, pulmonary 
tuberculosis 
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Mycobacterium tuberculosis is one of the most ubiqui- 
tous intracellular pathogens in the world. Roughly, one- 
third of the world’s population is infected with the 
bacillus, which is responsible for 8 to 12 million cases of 
active tuberculosis, and 3 million deaths per year.’ In the 
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majority of humans, an effective immune response devel- 
ops after infection with mycobacteria, restricting the 
spread of the pathogen. Approximately 1 of 10 infected 
people will develop active disease during their lifetime; 
however, only a minority of them possess a risk factor, 
such as advanced age, alcohol abuse, diabetes, human 
immunodeficiency virus (HIV) infection, or use of cortico- 
steroids2 In the remainder, a complex interaction of 
genetic and environmental factors probably causes the 
development of disease. Observed differences in the 
occurrence of tuberculosis infection among races as well 
as studies in twins suggest that genetic factors are perti- 
nent in susceptibility to tuberculosis3-’ Recent experi- 
mental evidence strongly supports a genetic basis for 
resistance to tuberculosis, but no specific genes govern- 
ing susceptibility have been identified.3-5+8-‘4 The human 
leukocyte antigen (III& system seems to be an important 
genetic marker. 15*i6 It also is known that the HLA-DR anti- 
gens regulate host response to infection of M. tuber- 
culosis through cell-mediated immunity.“-*j 
Studies on dependence between HLA phenotypes 
and tuberculosis in several populations have produced 
various and conflicting results. Hawkins and co-workers 
were unable to find an association between the HLA-DR 
system and disease, whereas Hafez and colleagues con- 
firmed a relation between the number of patients suf- 
fering from tuberculosis and the HLA-DR antigens.24x25 In 
these earlier studies, the HIA phenotype was determined 
by conventional techniques. Development of DNA-based 
methods has improved the validity of HLA-typing, which 
as yet has been performed only in Asian and Mexican 
populations.21~26-28 No such analysis has, up to now, been 
carried out in the other regionsI 
The aim of the present study was to determine 
whether there is any connection between the HLA sys- 
tem locus-DRBl and increased morbidity in pulmonary 
tuberculosis (PTB). 
MATERIALS and METHODS 
Subjects 
With the approval of the local ethics committee, 31 unre- 
lated patients hospitalized with newly detected active 
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PTB at the Department of Pulmonology of Medical Uni- 
versity, Gdansk, Poland, were studied. The patients were 
at a similar clinical stage and with similarly localized dis- 
ease on the initial chest radiograph (CXR) (the infiltrates 
with cavitation in one or two lung zones). The diagnosis 
of tuberculosis was confirmed in all patients by demon- 
stration of acid-fast bacilli (AFB) in sputum smears and by 
a positive sputum culture of the M. tuberculosis strains. 
After 2 months of therapy (rifampin, isoniazid, ethambu- 
tol, pyrazinamide), patients were examined again, and 
none of them showed either clinical or radiologic evi- 
dence of active PTB. In addition to symptomatic and 
radiographic improvement, disappearance of AFB from 
sputum smears, and the conversion of culture to negative 
were considered, to assess the response to therapy. None 
of the patients had a family history of tuberculosis or 
other related diseases. 
A total of 58 age- and sex-matched, unrelated healthy 
volunteers of the same socioeconomic status and ethnic 
background as the patients were included in the study as 
controls. These individuals were screened and recruited 
from university staff. Based on detailed clinical history, 
controls did not have a history of tuberculosis. None of 
them exhibited attributes of active PTB, based on clini- 
cal examination. All of them showed negative CXRs and 
no AFB in sputum. Comparative characteristics of patients 
with PTB and controls are shown in Table 1. 
All patients and controls were vaccinated with bacil- 
lus Calmette-Guerin (BCG). In Poland, since 1955, BCG 
vaccinations have been mandatory at birth and again at 
7, 12, and 18 years of age.“’ 
The Polish population is relatively homogenous and 
consists of no separate ethnic groups. Patients and con- 
trols included people living in the Gdansk area and in 
the neighboring districts. As a result of postwar move- 
ments, people were moving in from east, north, and cen- 
tral Poland; therefore, they may be considered 
representative of Poles as a whole. All patients and con- 
trols represented a homogenous Caucasian group.29 
Table 1. Comparative Characteristics of Patients 
with Pulmonary Tuberculosis and Controls 
PTB Patients Controls 
Parameter n =31 (%) n = 58 (%) 
Age 
Mean 40 Y 42 Y 
Range 22-66 y 27-60 y 
Gender 
Female 13 (42) 26 (45) 
Male 18 (58) 32 (55) 
Last BCG vaccination 31 (100) 58 (100) 
Positive PPD skin-test 31 (100) 0 
Symptoms 
Cough 29 0 
Fever 28 0 
Night sweats 31 0 
Weight loss 17 0 
BCG = bacille Calmette-Gukrin; PPD = purified protein deriVatiVe. 
Patients with PTB and controls were followed-up for 6 
months to confirm their diagnosis or control status. 
Informed consent was obtained from patients and con- 
trols who participated in this study. 
Tuberculin Skin Test 
All tuberculin tests were done by the Mantoux method, 
using two tuberculin units (TV> of human PPD Rtzs with 
Tween@SO (Statens Seuminstitut, Copenhagen). Two trans- 
verse diameters of induration were measured to the near- 
est millimeter. Any reaction of 10 mm or more was 
considered a positive test30 
Mycobacteriology 
All tests were performed using standard methods that 
did not change during the study period. Direct sputum 
smears were examined by light microscopy and by cul- 
tures on 7H11, Lowenstein-Jensen medium. All cultures 
were identified as catalase or peroxidase isoniazid (INH)- 
sensitive M. tuberculosis strains by standard tests.” The 
niacin production test for M. tuberculosis was used. The 
first culture with positive result was routinely tested for 
drug susceptibility to first-line drugs. No other biologic 
differences were observed in the M. tuberculosis strains. 
Chest Radiograph 
The initial and follow-up standard posteroanterior CXRs 
of the patients and controls were reviewed. Two physi- 
cians who were blinded to the clinical data of the study 
population evaluated the CXRs. The disease extent on 
the initial CXR was based on the number of lung zones 
involved; each lung was considered to have three zones 
(upper, middle, and lower). Involvement of one or two 
zones was considered to be localized disease, three or 
four zones as moderate disease, and five or six zones as 
extensive disease. Follow-up CXRs were classified as 
showing improvement, progression, or no change.“’ The 
presence or absence of infiltrate or cavitation was noted. 
Molecular HLA-DR Typing 
Molecular HLA-DRBl typing was carried out in the 
Department of Immunopathology of Medical University 
of Gdansk. 
Genomic DNA was extracted from 10 mL of periph- 
eral blood, using the salt extraction method.“* The DRBI 
typing was performed using sequence-specific amplifi- 
cation (polymerase chain reaction with sequence spe- 
cific primer [PCR-SSP], following the method of Olerup 
and Zetterquist.33 
The DRBl primers were supplied by DYNAL (Oslo, 
Norway) in the standard kit DYNAL@DR “low-resolution”- 
SSP (Cat no.550.01). Per-kin-Elmer (Branchville, New Jer- 
sey) Ampli Tuq DNA polymerase (5 U/yL) manufactured 
by Roche (Basel, Switzerland) was used. 
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The PCR reactions were carried out in 10 ~J,L vol- 
umes. Samples were amplified in Gene Amp PCR system 
2400 Perkin Elmer cycler. Samples were amplified after 
initial denaturation at 94°C for 2 minutes, followed by 10 
cycles of 94’C denaturation for 10 seconds, 65°C anneal- 
ing, and extension for 60 seconds, followed by 20 cycles 
of 94°C denaturation for 10 seconds, 61”~ annealing for 
50 seconds, and a final 72°C extension for 30 seconds. 
Amplification products were detected by agarose gel 
electrophoresis, with 2% agarose (Sigma A 9539, Sigma 
Chemical, St. Louis, MO) gel in 0.5X Tris-Borate-EDTA 
(TBE) buffer with ethidium bromide. The electrophore- 
sis was run in 0.5 X TBE buffer for 15 minutes at 10 V/cm. 
The gel was examined under ultraviolet illumination. 
Statistical Analysis 
The differences in phenotype frequencies of HLA anti- 
gens among the studied groups were analyzed using the 
chi-squared test after Yates’ correction.34 To correct the 
level of significance in the chi-squared test, to eliminate 
“significance by chance,” the probability values (p) were 
corrected by the use of the Bonferoni inequality method 
(i.e., multiplication with the number of antigens com- 
pared).35 A P-value of 0.05 or less was considered to be 
significant. The relative risk (RR) was defined based on 
Woolf’s method.36 
RESULTS 
Comparison of the frequency of HLA-DRBl antigens in 
the group of patients with PTB with the frequencies of 
these antigens in a control population is presented in 
Table 2. 
The DRBl*I6 alleles appear much more frequently in 
patients with PTB, and were observed in 5 of 31 patients 
with tuberculosis (16%) and in comparison to 2 of 58 
controls (3%) (P < 0.01). Moreover, DRBl*16-positive 
patients with PTB also had increased values of relative 
risk (RR = 9.7) of occurrence of the disease. The 
HLA-DRBl*l5 alleles were present with a similar fre- 
quency in both groups. When HLA-DR2 alleles were com- 
bined (i.e., the DRB1*15 and DRBl*l&positive patients 
with PTB), they were comparable with controls. 
Human leukocyte antigen DRBl*13 alleles were sig- 
nificantly less frequent in the patient group (l/31 cases) 
(3%) than in the healthy controls (17/58 [29%]; 
P < O.OOl), whereas the frequency of occurrence of the 
HLA-DRBl*14 alleles was similar in both groups. More- 
over, in patients with DRB1*13 alleles of HLA-DR6 anti- 
gen in phenotype decreased values of relative risk 
(RR = 0.04) was observed. When the DRB1*13 and 
DRB1*14 alleles were combined, there was a slight 
increase in HLA-DR6 alleles among the patients with PTB 
(3131 cases llO%l) compared with controls (20/58 [35%]) 
(x2 = 6.4; P > 0.05). 
Table 2. Phenotype Frequency of HLA-DR Antigens in Patients 
with Pulmonary Tuberculosis and Control Individuals from Poland 
PTB 
Patients Controls 
(n ,=oT 1) (n = 58) 
Serologic HLA No. 
DR DRB 7 Positive* Positive* 
TVpe Alleles % % RR X’ P 
DRl DRBl*Ol 2 (6) 9 (15) 0.37 0.09 NS 
DR2 DRB1*15 2 (6) 15 (26) 0.19 0.8 NS 
DRBl *16 8 (25) 2 (3) 9.73 8.0 <O.Ol 
DR3 DRB1*03 7(22) 15 (26) 0.58 0.47 NS 
DR4 DRB1*04 5(16) 10 (17) 0.92 0.01 NS 
DR5 DRBl*ll 6 (19) 16 (28) 0.63 0.73 NS 
DRBl*12 1 (3) 3 (5) 0.61 0.13 NS 
DR6 DRB1*13 1 (3) 17 (29) 0.04 20.5 <O.OOl 
DRB1*14 2 (6) 3 (5) 1.26 0.5 NS 
DR7 DRB1*07 7(22) lO(17) 1.40 0.37 NS 
DR 8 DRBl*08 2 (6) 4 (6) 0.93 1.56 NS 
DR 9 DRB1*09 0 (0) 111) 0 0.006 NS 
DRlO DRBl*iO 0 (0) 3 (5) 0 0.45 NS 
*Persons possessing the particular allele; NS = not significant (P > 0.05). 
Frequency comparison of the remaining HLA anti- 
gens in both populations failed to show statistical differ- 
ences. 
DISCUSSION 
One of the first reports on an association between the 
HLA class I antigens and tuberculosis was published by 
Selby and colleagues.“’ The association of tuberculosis 
with HLA class II antigens may be more relevant than 
that with HLA-A, B, C antigens, because cell-mediated 
immunity is known to be involved in the pathogenesis of 
tuberculosis.‘7-23 
Only few reports about association between HLA-DR 
antigens and tuberculosis have been published. One of 
the earlier studies showed an increased frequency of DR5 
in the Egyptian population with tuberculosis.25 Signifi- 
cant increase in frequency of HLA-DR5 in black American 
patients also has been reported.38 At the same time, asso- 
ciation of tuberculosis with the HLA-DR2 antigen was 
shown in studies conducted by Singh and colleagues in 
an Indian Hindu population3’ This association was con- 
firmed by observations of Khomenko et al in Russian and 
Asian populations and Bothamley et al in Indonesian 
patients with tuberculosis. *O,*’ Close association between 
DR2 and elevated levels of antibodies to epitopes on a 
38 kD protein specific to M. tuberculosis was demon- 
strated.41,42 However, the available literature does not 
show any link between DR2 appearance and tuberculo- 
sis in Western white populations.16J8.4” 
All these studies were based on serologic testing of 
expressed HLA antigens on the surface of lymphocytes, 
a method that, incidentally, shows about 20% discrepancy 
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with DR typing with the more sensitive molecular DNA- 
based methods.26,44 
Using PCR-based sequence-specific oligonucleotide 
probe hybridization (SSOP) technique, Goldfeld et al and 
Rajalingam et al obtained inconsistent results of the stud- 
ies on the association between the HLA-DR2 antigen and 
tuberculosis.21,26 In molecular typing, the HLA-DR2 anti- 
gen was more frequent in Asian Indian patients with 
tuberculosis than in controls.26 Goldfeld et al did not con- 
firm these data, but they showed that when HLA-DR2 
alleles were combined (i.e., the DRB1*15 with DRB1*16 
alleles), the HLADR2 antigen was slightly increased in 
the Cambodian population with tuberculosis.*’ However, 
no specific HLA-DR2 alleles were significantly increased 
in the patients tested by Goldfeld et al or by Rajalingam 
et al. Other researchers have found increased frequen- 
cies of DRB1*1501 allele in Mexican patients with PTB.28 
No link with HLA-DR2 gene occurred in studies con- 
ducted by Sanjeevi and colleagues in South Indians with 
F’TEI.*’ Also, the presence of HLA-DR5 in American black 
populations with PTB has not been confirmed by mole- 
cular studies.21*26,“6 Likewise, a negative correlation 
between M. tuberculosis and the HLA-DR6 antigen was 
disclosed by Hwang et al and Singh et a1.38,39 Also, the 
decreased HLA-DR3 antigen frequency in patients with 
PTB revealed by Khomenko and colleagues has not been 
confirmed by molecular typing.2’.26a40 
Results of the present study confirmed only some of 
the above observations. A comparable occurrence of the 
HLA-DR2 alleles and significantly lower appearance of 
HLA-DR6 alleles in patients with PTB versus controls was 
shown. Molecular methods (PCR-SSP) revealed that sub- 
types of HLA-DR2 and HLA-DR6 antigens in patients with 
PTB differ signifcantly. The DRB1*16 alleles were more, 
and DRB1*13 alleles less frequent in the PTB group, 
whereas the frequencies of DRB1*15 and DRB1*14 
alleles were comparable to those found in healthy indi- 
viduals. The results of this study contrast with those of 
Teran-Escandon et a1,28 who reported the lower expres- 
sion of DR4 and DR8 antigens in PTB. The frequency of 
HLA-DR3 and HLA-DR5 antigens among patients in the 
present study also was similar to the values noted in the 
control group. Differences between these results could be 
attributable to several factors, including the population 
variability of HLA association with PTB within popula- 
tions, the socioeconomic status of the patients, as well as 
specificity and sensitivity of applied methods. 
In summary, results demonstrate that the presence 
of DRB1*16 allele of the HLADR2 antigen may be related 
to a higher relative risk (RR = 9.7) of developing PTB. A 
low relative risk of disease development with DRB1*13 
alleles of HLA-DR6 antigen may suggest its link to the 
genes of resistance to tuberculosis. However, further stud- 
ies are necessary using more precise molecular methods 
and in a larger group of patients with PTB. 
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